[Transcatheter closure of patent ductus arteriosus using the Amplatzer duct occluder in children: initial and one-year results]. / Cierre percutáneo del conducto arterioso persistente con dispositivo Amplatzer en niños: resultados inmediatos y a un año.

OBJECTIVE: Percutaneous closure of patent ductus arteriosus (PDA) is a well established technique. Our objective was to determine the safety and efficacy of the Amplatzer occluder for the treatment of PDA in children. METHODS: From November 2005 to June 2007 we reviewed the clinical records of 39 patients (23 girls and 16 boys), with a mean age of 19.8 +/- 13.7 months and weight 9.2 +/- 3.2 Kg, who underwent percutaneous closure of a PDA with an Amplatzer device. The forty one percent of the patients (16/39) were < or = 1 year of age, and 71.8 % (28/39) weighed < or = 10 Kg. The age of children with body weight < or = 10 Kg was 13.1 +/- 6.1 months (range 5-33 months). The morphology of the PDA was determined by a lateral aortogram and classified according to Krichenko. All the patients were followed-up with radiologic and echocardiographic control at 24 hours, 1, 3, 6 and 12 months postinsertion (median 20 months). RESULTS: The PDA diameter ranged between 2.0 mm to 12 mm (3.6 mm +/- 2.0 mm) in the 39 patients included. PDA types according to Krichenko were: type A = 25 (64.1%), type B = 1 (2.6%), type C = 5 (12.8%), type D = 2 (5.1%) and type E = 3 (7.7%). Three patients had a residual PDA post-surgical closure attempt. Qp/Qs ratio was 2.4 +/- 1.5 (range 1.0-6.7) and the relation PSP/PSS was 0.49 +/- 0.18 (range: 0.21-0.87). Pulmonary hypertension was present in 16 patients (41%). The Amplatzer occluder was implanted successfully in 36/39 patients (92.3%). The procedure failed in three cases: 1) difficulty to place the device due to wrong assessment of the ductus size; 2) difficulty to advance the device due to angulation (kinking) of the releasing system; 3) migration of the device to descending aorta. The mean time of fluoroscopy and for the entire procedure was 13.2 +/- 6.3 minutes and 65.3 +/- 21.9 minutes, respectively. There were no deaths with the procedure. Minor and mayor complications occurred in eight patients, all of them but one, in children with body weight < or = 10 Kg. In the 36 successful insertions an aortogram showed complete occlusion in 26 (66.7%), trivial leak through the occluder in 6 (15.45), mild leak in 4 (10.3%), and moderate leak in 2 (5.1%). A control echocardiogram 24 h after the insertion showed a successful rate of 82.1% (32/36). Complete occlusion of the PDA was obtained in 35/36 patients (97.2%) at 3 months follow-up study. In 4 patients the percutaneous occlusion technique did not result in PDA closure, and 3 of them underwent a surgical closure. On follow-up, 3 patients developed mild stenosis of the left pulmonary artery and two a mild pressure gradient in the descending aorta. CONCLUSIONS: Percutaneous closure of PDA with an Amplatzer is a safe and effective technique. In children with ductus arteriosus diameter > or = 2 mm the Amplatzer device should be recommended over surgical closure. The incidence of complications after the procedure is higher in patients under 10 kg of body weight.

Transcatheter closure of patent ductus arteriosus using the amplatzer duct occluder in infants under 1 year of age.

INTRODUCTION AND OBJECTIVES: Percutaneous closure of patent ductus arteriosus (PDA) is a well-established technique. We evaluated the usefulness of the Amplatzer duct occluder for the percutaneous closure of patent ductus arteriosus in 29 children under 1 year of age. METHODS: The patients' mean age was 8.9+/-2.8 months and their mean weight was 6.4+/-1.5 kg. In addition, 24.1% of patients were aged 6 months or less and 17.2% weighed 5 kg or less. All completed follow-up (0.5-36 months). RESULTS: The minimum PDA diameter was 3.16+/-1.24 mm. The device was implanted successfully in 26 patients (89.6%). Failures were due to either the device migrating to the descending aorta, persistent moderate leakage, or to difficulty in the advancement of the device. No deaths were associated with the procedure. Three major complications occurred in two patients (10.3%). Aortography showed initial total occlusion in 65.5% of patients. At 3-month follow-up, total occlusion was observed in 96.1% of patients. Ultimately, closure was achieved successfully in 25 of the 29 patients (86.2%). During follow-up, four patients exhibited mild left pulmonary artery stenosis and one exhibited mild stenosis of the descending aorta. CONCLUSIONS: In children under 1 year of age, percutaneous closure of patent ductus arteriosus using an Amplatzer occluder was a safe and effective procedure. It is possible that improvements in the design of the occluder could decrease the complication rate.

Cierre transcatéter del conducto arterioso persistente con dispositivo de Amplatzer en niños menores de un año / Transcatheter closure of patent ductus arteriosus using the amplatzer duct occluder in infants under one year of age

Introducción y objetivos. El cierre percutáneo del conducto arterioso persistente (CAP) es una técnica bien establecida. Evaluamos la utilidad del oclusor de Amplatzer (ADO), en el cierre percutáneo del CAP en 29 niños menores de 1 año. Métodos. La edad de los pacientes fue de 8,9 ± 2,8 meses y el peso, 6,4 ± 1,5 kg. El 24,1% de los pacientes con edad ≤ 6 meses y el 17,2%, con peso ≤ 5 kg. Se realizó seguimiento en todos (0,5-36 meses). Resultados. El diámetro mínimo del conducto fue 3,16 ± 1,24 mm. El dispositivo se implantó con éxito en 26 (89,6%) pacientes. Las causas del fracaso se debieron a migración del dispositivo a la aorta descendente, persistencia de la fuga en forma moderada y dificultad en progresar el dispositivo. La mortalidad fue nula con el procedimiento. Ocurrieron 3 complicaciones mayores en 2 (10,3%) pacientes. Un aortograma mostró oclusión completa inicial en el 65,5% de los pacientes. La oclusión completa del conducto se demostró en el 96,1% de los pacientes al tercer mes de seguimiento. El éxito final del cierre del CAP se logró en 25/29 (86,2%) pacientes. En el seguimiento, 4 pacientes mostraron estenosis leve en la rama pulmonar izquierda, y 1, estenosis leve en la aorta descendente. Conclusiones. En niños menores de 1 año, el cierre percutáneo del CAP con el oclusor de Amplatzer es un procedimiento efectivo y seguro. Las mejoras en el diseño del oclusor posiblemente disminuirán la frecuencia de complicaciones (AU)

Introduction and objectives. Percutaneous closure of patent ductus arteriosus (PDA) is a well-established technique. We evaluated the usefulness of the Amplatzer duct occluder for the percutaneous closure of patent ductus arteriosus in 29 children under 1 year of age. Methods. The patients’ mean age was 8.9 [2.8] months and their mean weight was 6.4 [1.5] kg. In addition, 24.1% of patients were aged 6 months or less and 17.2% weighed 5 kg or less. All completed follow-up (0.5-36 months). Results. The minimum PDA diameter was 3.16[1.24] mm. The device was implanted successfully in 26 patients (89.6%). Failures were due to either the device migrating to the descending aorta, persistent moderate leakage, or to difficulty in the advancement of the device. No deaths were associated with the procedure. Three major complications occurred in two patients (10.3%). Aortography showed initial total occlusion in 65.5% of patients. At 3-month follow-up, total occlusion was observed in 96.1% of patients. Ultimately, closure was achieved successfully in 25 of the 29 patients (86.2%). During follow-up, 4 patients exhibited mild left pulmonary artery stenosis and 1 exhibited mild stenosis of the descending aorta. Conclusions. In children under 1 year of age, percutaneous closure of patent ductus arteriosus using an Amplatzer occluder was a safe and effective procedure. It is possible that improvements in the design of the occluder could decrease the complication rate (AU)

Cierre percutáneo del conducto arterioso persistente con dispositivo Amplatzer en niños: resultados inmediatos y a un año / Transcatheter closure of patent ductus arteriosus using the Amplatzer duct occluder in children: initial and one-year results

OBJECTIVE: Percutaneous closure of patent ductus arteriosus (PDA) is a well established technique. Our objective was to determine the safety and efficacy of the Amplatzer occluder for the treatment of PDA in children. METHODS: From November 2005 to June 2007 we reviewed the clinical records of 39 patients (23 girls and 16 boys), with a mean age of 19.8 +/- 13.7 months and weight 9.2 +/- 3.2 Kg, who underwent percutaneous closure of a PDA with an Amplatzer device. The forty one percent of the patients (16/39) were < or = 1 year of age, and 71.8 % (28/39) weighed < or = 10 Kg. The age of children with body weight < or = 10 Kg was 13.1 +/- 6.1 months (range 5-33 months). The morphology of the PDA was determined by a lateral aortogram and classified according to Krichenko. All the patients were followed-up with radiologic and echocardiographic control at 24 hours, 1, 3, 6 and 12 months postinsertion (median 20 months). RESULTS: The PDA diameter ranged between 2.0 mm to 12 mm (3.6 mm +/- 2.0 mm) in the 39 patients included. PDA types according to Krichenko were: type A = 25 (64.1%), type B = 1 (2.6%), type C = 5 (12.8%), type D = 2 (5.1%) and type E = 3 (7.7%). Three patients had a residual PDA post-surgical closure attempt. Qp/Qs ratio was 2.4 +/- 1.5 (range 1.0-6.7) and the relation PSP/PSS was 0.49 +/- 0.18 (range: 0.21-0.87). Pulmonary hypertension was present in 16 patients (41%). The Amplatzer occluder was implanted successfully in 36/39 patients (92.3%). The procedure failed in three cases: 1) difficulty to place the device due to wrong assessment of the ductus size; 2) difficulty to advance the device due to angulation (kinking) of the releasing system; 3) migration of the device to descending aorta. The mean time of fluoroscopy and for the entire procedure was 13.2 +/- 6.3 minutes and 65.3 +/- 21.9 minutes, respectively. There were no deaths with the procedure. Minor and mayor complications occurred in eight patients, all of them but one, in children with body weight < or = 10 Kg. In the 36 successful insertions an aortogram showed complete occlusion in 26 (66.7%), trivial leak through the occluder in 6 (15.45), mild leak in 4 (10.3%), and moderate leak in 2 (5.1%). A control echocardiogram 24 h after the insertion showed a successful rate of 82.1% (32/36). Complete occlusion of the PDA was obtained in 35/36 patients (97.2%) at 3 months follow-up study. In 4 patients the percutaneous occlusion technique did not result in PDA closure, and 3 of them...

Transcatheter closure of patent ductus arteriosus using the amplatzer duct occluder in infants under one year of age.

INTRODUCTION AND OBJECTIVES: Percutaneous closure of patent ductus arteriosus (PDA) is a well-established technique. We evaluated the usefulness of the Amplatzer duct occluder for the percutaneous closure of patent ductus arteriosus in 29 children under 1 year of age. METHODS: The patients' mean age was 8.9±2.8 months and their mean weight was 6.4±1.5kg. In addition, 24.1% of patients were aged 6 months or less and 17.2% weighed 5kg or less. All completed follow-up (0.5-36 months). RESULTS: The minimum PDA diameter was 3.16±1.24 mm. The device was implanted successfully in 26 patients (89.6%). Failures were due to either the device migrating to the descending aorta, persistent moderate leakage, or to difficulty in the advancement of the device. No deaths were associated with the procedure. Three major complications occurred in two patients (10.3%). Aortography showed initial total occlusion in 65.5% of patients. At 3-month follow-up, total occlusion was observed in 96.1% of patients. Ultimately, closure was achieved successfully in 25 of the 29 patients (86.2%). During follow-up, four patients exhibited mild left pulmonary artery stenosis and one exhibited mild stenosis of the descending aorta. CONCLUSIONS: In children under 1 year of age, percutaneous closure of patent ductus arteriosus using an Amplatzer occluder was a safe and effective procedure. It is possible that improvements in the design of the occluder could decrease the complication rate.